{
    "root": "2f2711fd-44b7-517f-e063-6294a90a0982",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Clopidogrel Bisulfate",
    "value": "20250227",
    "ingredients": [
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "HYDROGENATED CASTOR OIL",
            "code": "ZF94AP8MEY"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED",
            "code": "2165RE0K14"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "CLOPIDOGREL BISULFATE",
            "code": "08I79HTP27"
        }
    ],
    "indications": "clopidogrel tablets p2y 12 platelet inhibitor indicated : \u25cf acute coronary syndrome \u2013 patients non\u2013st-segment elevation acs ( unstable angina [ ua ] /non\u2013st-elevation myocardial infarction [ nstemi ] ) , clopidogrel tablets shown reduce rate myocardial infarction ( myocardial infarction ) stroke . ( 1.1 ) \u2013 patients st-elevation myocardial infarction ( stemi ) , clopidogrel tablets shown reduce rate myocardial infarction stroke . ( 1.1 ) \u25cf recent myocardial infarction , recent stroke , established peripheral arterial disease . clopidogrel tablets shown reduce rate myocardial infarction stroke . ( 1.2 )",
    "contraindications": "\u25cf acute coronary syndrome ( 2.1 ) \u2013 initiate clopidogrel tablets single 300 mg oral loading dose continue 75 mg daily . \u2013 initiating clopidogrel tablets without loading dose delay establishment antiplatelet effect several days . \u25cf recent myocardial infarction , recent stroke , established peripheral arterial disease : 75 mg daily orally without loading dose . ( 2.2 )",
    "warningsAndPrecautions": "clopidogrel tablets , usp 75mg available light pink colored , round , beveled edge , biconvex film coated tablets printed `` 41 `` black ink one side plain side . tablets provided follows : bottles 30 ndc 43063-371-30 bottles 60 ndc 43063-371-60 bottles 90 ndc 43063-371-90 store 20\u00b0 25\u00b0 c ( 68\u00b0 77\u00b0 f ) ; excursions permitted 15\u00b0 30\u00b0 c ( 59\u00b0 86\u00b0 f ) [ usp controlled room temperature ] .",
    "adverseReactions": "active pathological bleeding , peptic ulcer intracranial hemorrhage ( 4.1 ) hypersensitivity clopidogrel component product ( 4.2 )",
    "indications_original": "Clopidogrel tablets are\u00a0 P2Y 12 platelet inhibitor indicated for: \u25cf\u00a0 Acute coronary syndrome \u2013 For patients with non\u2013ST-segment elevation ACS (unstable angina [UA]/non\u2013ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets have been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) \u2013 For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets have been shown to reduce the rate of MI and stroke. ( 1.1 ) \u25cf\u00a0 Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets have been shown to reduce the rate of MI and stroke. ( 1.2 )",
    "contraindications_original": "\u25cf\u00a0\u00a0\u00a0 Acute coronary syndrome ( 2.1 ) \u2013 Initiate clopidogrel tablets with a single 300 mg oral loading dose and then continue at 75 mg once daily. \u2013\u00a0 Initiating clopidogrel tablets without a loading dose will delay establishment of an antiplatelet effect by several days. \u25cf\u00a0 Recent MI, recent stroke, or established peripheral arterial disease:\u00a0 75 mg once daily orally without a loading dose. ( 2.2 )",
    "warningsAndPrecautions_original": "Clopidogrel tablets, USP 75mg are available as light pink colored, round, beveled edge, biconvex film coated tablets printed \"41\" with black ink on one side and plain on the other side. Tablets are provided as follows:\n                                          Bottles of 30                                      NDC 43063-371-30\n                                          Bottles of 60                                      NDC 43063-371-60\n                                          Bottles of 90                                      NDC 43063-371-90\n                  \n                  Store at 20\u00b0 to 25\u00b0 C (68\u00b0 to 77\u00b0 F); excursions permitted to 15\u00b0 to 30\u00b0 C (59\u00b0 to 86\u00b0 F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage ( 4.1 ) Hypersensitivity to clopidogrel or any component of the product ( 4.2 )"
}